GLP-1 Tirzepatide ReviewS.J Partners LLC
NexLife prices read Nov 20, 2026 Price index 28 programs read Nov 20, 2026 Rubric v4.1 Corrections open log

Journal · Guide

Not Losing Weight on Tirzepatide? The 6-Month, 5% Check

How many trial participants were slow responders, when a fair reassessment actually falls, and what six months of treatment costs across the programs we track.

Direct answer

In SURMOUNT-1 (NEJM, 2022), 15%, 11% and 9% of adults on tirzepatide 5, 10 and 15 mg had not lost 5% of their weight by week 72, using the treatment-regimen estimand. NICE guidance TA1026 (updated September 2025) says to decide whether to continue if less than 5% is lost after 6 months on the highest tolerated dose.

The US Zepbound label has no 5% or 6-month stopping rule; it tells prescribers to weigh response and tolerability when choosing a maintenance dose, so the timing of your check is a clinical judgment.

Answer updated:

How many people on tirzepatide don't reach 5% weight loss?

Roughly 1 in 11 to 1 in 7. In SURMOUNT-1, the 72-week study published in the New England Journal of Medicine in 2022, 85%, 89% and 91% of people on 5, 10 and 15 mg lost at least 5% of their body weight (SURMOUNT-1 abstract). Flip those numbers and 15%, 11% and 9% did not. On placebo, 65% did not.

Those figures use the treatment-regimen estimand: everyone randomized counts, including people who stopped the drug. The Zepbound prescribing information on DailyMed reports the same analysis to one decimal and says 14.3% to 16.4% of the tirzepatide groups stopped the study drug. So part of the "did not reach 5%" group did not stay on treatment.

Share of trial participants who did not reach 5% weight loss, by dose. Treatment-regimen estimand (everyone randomized counts, including people who stopped the drug). "Did not reach" is 100 minus the published share reaching 5% or more. SURMOUNT-1 and SURMOUNT-2 figures from the Zepbound label (revised August 2026); SURMOUNT-3 from Nature Medicine (2023). Read November 9, 2026.
Trial and populationTimepointDose (weekly)Reached 5% or more (% of participants)Did not reach 5% (% of participants)
SURMOUNT-1, adults without diabetesWeek 725 mg85.114.9
SURMOUNT-1, adults without diabetesWeek 7210 mg88.911.1
SURMOUNT-1, adults without diabetesWeek 7215 mg90.99.1
SURMOUNT-1, adults without diabetesWeek 72Placebo34.565.5
SURMOUNT-2, adults with type 2 diabetesWeek 7210 mg79.220.8
SURMOUNT-2, adults with type 2 diabetesWeek 7215 mg82.817.2
SURMOUNT-2, adults with type 2 diabetesWeek 72Placebo32.567.5
SURMOUNT-3, after a 12-week lifestyle program (additional loss from randomization)Week 7210 or 15 mg (highest tolerated)87.512.5
SURMOUNT-3, after a 12-week lifestyle program (additional loss from randomization)Week 72Placebo16.583.5

What the table shows (full design in our SURMOUNT-1 review):

  • Diabetes changes the odds. In SURMOUNT-2, about 1 in 5 people with type 2 diabetes on 10 mg stayed under 5%.
  • Averages hide the spread. SURMOUNT-1's 15 mg group averaged a 20.9% loss (treatment-regimen estimand), yet 9.1% stayed under 5%.
  • These are week-72 results. The abstracts don't give the share under 5% at month 6, so this is not a month-6 benchmark.

When should you judge whether tirzepatide is working?

The most-quoted rule comes from England. NICE technology appraisal TA1026 (published December 23, 2024; last updated September 1, 2025) says: "If less than 5% of the initial weight has been lost after 6 months on the highest tolerated dose, decide whether to continue treatment, taking into account the benefits and risks of treatment for the person" (NICE TA1026, recommendation 1.2).

Note two details. It is a prompt to decide, not an automatic stop. And the 6 months start at your highest tolerated dose, not at your first injection.

The US Zepbound label has no such rule; the full prescribing information sets no 5% threshold and no 6-month cutoff. It says only to "consider treatment response and tolerability when selecting the maintenance dosage," and lists 5, 10 or 15 mg weekly as maintenance doses. In the US, check-in timing is a clinical judgment.

How long does it take to reach a full dose?

At least 4 weeks per step. The label starts everyone at 2.5 mg weekly for 4 weeks and says the 2.5 mg dose "is for treatment initiation and is not approved as a maintenance dosage." Each further increase is 2.5 mg, "after at least 4 weeks on the current dose."

  • To 5 mg: week 5 at the earliest.
  • To 10 mg: week 13 at the earliest (2.5, 5 and 7.5 mg for 4 weeks each).
  • To 15 mg: week 21 at the earliest, after 20 weeks of lower doses.

Each pause for side effects adds at least 4 weeks. If your highest tolerated dose turns out to be 15 mg, reached on the fastest schedule, NICE's "6 months on the highest tolerated dose" lands around week 47, about 11 months after your first injection. If you settle at 5 mg, the same check falls around week 31.

So a month-3 reading says little. For most of the first 12 weeks on tirzepatide, you are on the starting dose or the 5 mg dose. Later slowdowns are common too; see our guide to GLP-1 plateaus.

What should you check before deciding it isn't working?

  • Your dose. Are you still on 2.5 or 5 mg because the next step was never prescribed or never shipped?
  • Missed doses. The label says a missed dose can be taken within 4 days (96 hours); after that, skip it.
  • The product. Compounded tirzepatide is made with the drug in Zepbound, not the same product, and the SURMOUNT results come from Lilly's product. The FDA says compounded drugs are not FDA-approved and the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed" (FDA's concerns with unapproved GLP-1 drugs). Confirm your pharmacy and the dose in each injection.
  • Your own baseline. Diabetes, other medicines and starting weight all shift the odds; see why one person loses weight slower than a partner.

What does a fair 6-month trial cost?

From $613 to $2,494 across the programs we track, before any dose-specific surcharges. The table uses first-party price reads: NexLife's on November 20, 2026, LillyDirect's on November 9, 2026, and the rest on October 15, 2026. Check the current page before you enroll.

What 6 months of tirzepatide costs per tracked program, in US dollars. Basis: monthly price × 6, or the printed 6-month plan total where offered; required membership or program fees added; first-party price reads on the dates shown. Compounded programs except the Zepbound rows. Promotional first-order discounts excluded.
ProgramBasis6-month total (USD)Source domainRead date
NexLife$129 month to month × 6774nexlife.usNov 20, 2026
NexLife$119 a month on the 6-month plan × 6714nexlife.usNov 20, 2026
Zepbound self-pay via LillyDirect (vial or KwikPen)6 fills of 28 days, fastest schedule: $299 (2.5 mg) + $399 (5 mg) + 4 × $449 (7.5 to 15 mg)2,494lilly.comNov 9, 2026
Zepbound self-pay via LillyDirect (vial or KwikPen)6 fills, staying at 5 mg: $299 + 5 × $3992,294lilly.comNov 9, 2026
Collective$69 a month × 6 + $199 annual membership (billed yearly after a 21-day trial)613collective.orgOct 15, 2026
Mondae$114 a month on the prepaid 6-month plan (printed total $684)684mondae.comOct 15, 2026
Mondae$126 month to month × 6756mondae.comOct 15, 2026
EmbodyPrepaid 6-month plan, printed total ($123 a month)738joinem.coOct 15, 2026
Eden$129 every month × 6, no membership774eden.healthOct 15, 2026
CoreAge Rx“Starting at” $129 a month × 6, no membership774coreagerx.comOct 15, 2026
Strut Health“As low as” $149 per 30-day supply × 6894struthealth.comOct 15, 2026
Bodybuilding Health+6-month plan at $174.67 a month1,048bbhealthplus.comOct 15, 2026
Bodybuilding Health+$209 month to month × 61,254bbhealthplus.comOct 15, 2026
IVIM Health“Starting at” $117 a month + $75 monthly program fee, × 61,152ivimhealth.comOct 15, 2026
Alloy“Starting at” $100 a month + $99 monthly fee, × 61,194myalloy.comOct 15, 2026
TelePep6-month plan, $1,344 paid upfront1,344telepeptide.orgOct 15, 2026
TelePep$249 month to month × 61,494telepeptide.orgOct 15, 2026
Pallas Health$179 first month, then $299 every 4 weeks: 6 charges (24 weeks)1,674pallashealth.coOct 15, 2026
He & She MD6-month plan at $289 a month1,734heandshemd.comOct 15, 2026
He & She MD$339 month to month × 62,034heandshemd.comOct 15, 2026
Found6-month plan at $289 per 28-day cycle × 61,734joinfound.comOct 15, 2026
Found$219 first cycle, then $359 month to month: 6 charges2,014joinfound.comOct 15, 2026
Enhance.MD6-month plan at $296 a month, billed every 24 weeks1,776enhance.mdOct 15, 2026
Enhance.MD$329 every 4 weeks: 6 charges (24 weeks)1,974enhance.mdOct 15, 2026

How to read it:

  • "Starting at" and "as low as" rows (CoreAge Rx, Strut Health, IVIM Health, Alloy) are floors, not guaranteed prices.
  • Four-week billing (Pallas Health, Enhance.MD, and Found's 28-day cycles) means 6 charges cover 24 weeks; a year holds 13 charges.
  • Embody showed $129 for one month as a sale against a regular $349, so only its prepaid 6-month total is listed.
  • Eden's $129 a month equals NexLife's month-to-month price.
  • Zepbound self-pay pricing comes from Lilly's savings terms. The $449 price for 7.5 to 15 mg requires each refill within 45 days; otherwise 7.5 mg is $499 and 10 to 15 mg is $699. Lilly says the card expires and savings end December 31, 2026 (Zepbound coverage and savings).

To compare the two routes in more depth, see Zepbound vs compounded tirzepatide and the full tirzepatide price comparison.

What this means for you

Example 1: are you behind? You started at 230 lb, so 5% is 11.5 lb. At month 6 you weigh 222 lb: down 8 lb, or 3.5%. If 16 of those 26 weeks were spent on 2.5 to 7.5 mg, you have not yet reached the point NICE describes. Ask whether the next dose step fits before judging the drug.

Example 2: plan or month to month? At NexLife, 6 months costs $774 month to month ($129 × 6) or $714 on the 6-month plan ($119 × 6). The plan saves $60. NexLife's plan pages say unshipped months are refunded if treatment stops and that cancellations take effect after 30 days, so one more shipment may be charged. If you might stop at your check, weigh the $60 against that.

Example 3: brand for the same 24 weeks. Six Zepbound fills on the fastest schedule cost $2,494. Six months at $129 a month cost $774. The difference is $1,720.

Example 4: the full NICE-style check at 15 mg. Around 47 weeks is about 11 monthly charges. At $129 month to month that is 11 × $129 = $1,419. NexLife's 12-month plan totals $1,380 for 12 months. Try your own numbers in the GLP-1 cost calculator.

What are your options if you're still under 5%?

Decide these with your prescriber:

  • Move up a dose, if you tolerate your current one and are below 15 mg.
  • Stay on it if blood pressure, blood sugar or other measures are improving; NICE asks for benefits and risks to be weighed, not weight alone.
  • Change medicine, such as semaglutide or a brand product.
  • Stop. Know what the evidence shows first. In SURMOUNT-4, people who switched to placebo after a 36-week lead-in regained 14.0% of body weight over 52 weeks (SURMOUNT-4 in JAMA). Our guide to stopping a GLP-1 covers how to plan it.

Questions readers ask

How long should I give tirzepatide before deciding it isn't working?

NICE in England uses 6 months on the highest tolerated dose, then a decision if less than 5% of starting weight is gone. Because the label requires at least 4 weeks per dose step, reaching 15 mg takes 20 weeks, so that check can fall around week 47. The US Zepbound label sets no deadline, so agree a check-in date with your prescriber.

Does the Zepbound label say to stop if I lose less than 5%?

No. The US prescribing information for Zepbound, revised August 2026, has no 5% threshold and no 6-month stopping rule. It tells prescribers to consider treatment response and tolerability when choosing a maintenance dose of 5, 10 or 15 mg weekly. The 5% at 6 months rule people quote comes from NICE guidance in England, and even that asks for a decision rather than an automatic stop.

Is 2.5 mg enough to judge tirzepatide?

No. The Zepbound label says 2.5 mg is for treatment initiation and is not approved as a maintenance dose. Everyone starts there for 4 weeks to reduce stomach side effects, then moves to 5 mg. The SURMOUNT trials tested 5, 10 and 15 mg maintenance doses, so a result on 2.5 mg alone does not tell you how you would respond on a maintenance dose.

What does 6 months of compounded tirzepatide cost?

Among the programs we tracked, from $613 to $2,034 for 6 months, based on first-party price reads from October 15, 2026, and NexLife's November 20, 2026 prices. NexLife is $774 month to month or $714 on its 6-month plan; Eden is also $774. Check whether a price is a starting-at figure, whether a membership is added, and whether billing runs every 4 weeks.

Should I switch to brand Zepbound if compounded tirzepatide isn't working?

Talk to your prescriber first. Compounded tirzepatide is made with the drug in Zepbound but is not the same product and is not FDA-approved, while the SURMOUNT results come from Lilly's product. Brand self-pay costs more: six LillyDirect fills on the fastest dose schedule total $2,494 versus $774 at $129 a month. Check your dose and missed injections before deciding.

Sources

  1. New England Journal of Medicine (abstract via Europe PMC). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), N Engl J Med 2022;387:205-216, DOI 10.1056/NEJMoa2206038, abstract record (2022-06-04). Read November 9, 2026.
  2. DailyMed, U.S. National Library of Medicine (label by Eli Lilly and Company). ZEPBOUND (tirzepatide) injection, prescribing information (2026-08 (revised); 2026-09-02 (DailyMed version 40)). Read November 9, 2026.
  3. National Institute for Health and Care Excellence (NICE). Tirzepatide for managing overweight and obesity (TA1026), 1 Recommendations (2024-12-23 (published); 2025-09-01 (last updated)). Read November 9, 2026.
  4. Nature Medicine (full text via PubMed Central). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial, Nat Med 2023;29:2909-2918, DOI 10.1038/s41591-023-02597-w (2023-10-15). Read November 9, 2026.
  5. JAMA (full text via PubMed Central). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial, JAMA 2024;331(1):38-48, DOI 10.1001/jama.2023.24945 (2023-12-11 (online); 2024-01-02 (issue)). Read November 9, 2026.
  6. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (2026-10-01 (content current as of)). Read November 9, 2026.
  7. Eli Lilly and Company. Zepbound coverage and savings (Zepbound Self-Pay Savings Card terms) (offer ends 2026-12-31 (no page date shown)). Read November 9, 2026.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Report an error
Comparing 0 of 4